Key result
CHOP chemotherapy with a cumulative doxorubicin dose ≥100 mg/m2 reduced Global Longitudinal Strain from -19.62% to -18.03% in NHL patients, indicating subclinical left ventricular dysfunction.
Why the study?
Doxorubicin in the CHOP regimen remains standard first-line chemotherapy for non-Hodgkin lymphoma but has cardiotoxicity side-effects, prompting investigation into its effect on GLS reduction.
Does CHOP chemotherapy with cumulative doxorubicin ≥ 100 mg/m2 reduce global longitudinal strain in patients with Non-Hodgkin Lymphoma?
Cohort (n=30)
No
Does CHOP chemotherapy with cumulative doxorubicin ≥ 100 mg/m2 reduce global longitudinal strain in patients with Non-Hodgkin Lymphoma?
Absolute Event Rate: -18.03% vs -19.62%
Global longitudinal strain can detect early subclinical left ventricular dysfunction in NHL patients receiving doxorubicin-based chemotherapy before significant LVEF reductions occur.
GLS decline after low-dose doxorubicin in NHL may flag early cardiotoxicity; leaves open whether strain monitoring improves outcomes.
Background: Doxorubicin in CHOP regimen is still the golden standard of first-line chemotherapy in patients with NHL (Non-Hodgkin Lymphoma); however, it has enormous cardiotoxicity side-effects. Objective: This study aims to investigate the effect of CHOP chemotherapy implementation towards the GLS reduction in cumulative dosage of doxorubicin ? 100 mg/m. Method: This study was pre experimental analysis with modified cohort. The subjects were observed for 1 month, since the first chemotherapy until 1 week after the second chemotherapy. The echocardiogram procedure with ejection fraction and global longitudinal strain was conducted twice which was before the first chemotherapy and 1 week after the second chemotherapy. Results: The implementation of CHOP therapy with the cumulative dosage of ?100 mg/m2 has resulted in reduced GLS from 19.62% to -18.03%. The reduction of GLS>10% was 40% while the LVEF has not been obtained any reduction > 10%. The case of subclinical left ventricular dysfunctions was attained 16%. Conclusion: The implementation of CHOP chemotherapy with the dosage of ?100mg/m2 has been proved to cause reduced GLS and subclinical left ventricular dysfunctions.
No takes yet. Share an insight, caveat, or question.
Muhammad Perdana Airlanga (2020) conducted a cohort in Non-Hodgkin Lymphoma (n=30). CHOP chemotherapy vs. Baseline (pre-chemotherapy) was evaluated on Global Longitudinal Strain (GLS). CHOP chemotherapy with a cumulative doxorubicin dose ≥100 mg/m2 reduced Global Longitudinal Strain from -19.62% to -18.03% in NHL patients, indicating subclinical left ventricular dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: